Source link : https://www.newshealth.biz/health-news/another-win-for-antibody-drug-conjugate-in-her2-breast-cancer-with-brain-mets/
Trastuzumab deruxtecan (Enhertu, T-DXd) therapy produced “substantial and durable” overall and intracranial clinical activity in patients with HER2-positive advanced breast cancer, according to data from the DESTINY-Breast12 trial. Patients had stable and active brain metastases at baseline in the phase IIIb/IV study. The estimated overall median progression-free survival (PFS) was 17.3 months in patients who […]
Author : News Health
Publish date : 2024-09-14 18:46:35
Copyright for syndicated content belongs to the linked Source.